If Todos indeed become very successful in COVID space bring in substantial revenue, what incentives will they have to go through the deal to acquire remaining share of Breakthrough diagnostics giving AMBS a 49% controlling interest (at least for a while). My guess is that pie will shrink quite a bit unless GC speeds up Todos up listing.